Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
- PMID: 19408049
- DOI: 10.1245/s10434-009-0478-5
Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
Abstract
Background: Cytoreductive surgery (CRS) including gastric resection combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the prognosis of selected patients with peritoneal surface malignancies. Perioperative morbidity of this aggressive treatment strategy is high; however, overall mortality can be low in specialized centers. The aim of this study was to assess the safety of gastric resections with anastomosis during CRS and HIPEC.
Methods: Between 2005 and 2008, 204 patients underwent CRS and HIPEC at our tertiary referral centre. Of these, 37 procedures (male/female 24/13, median age 55 years) included gastric resections. The clinical data of all patients were introduced into a database and analyzed with respect to the morbidity associated with the gastric resections.
Results: Of all patients included, 16 had pseudomyxoma peritonei, 11 gastric carcinoma, 4 ovarian carcinoma, 3 malignant peritoneal mesothelioma, and 3 colon carcinoma. Twenty-seven patients had previous surgery (n = 22) and/or systemic chemotherapy (n = 18). Fifteen total gastrectomies, 3 subtotal gastrectomies, 12 distal gastrectomies, and 7 gastric wedge resections were performed during CRS. The overall postoperative morbidity was 45%; main surgical complications were pancreatitis (n = 6), abdominal abscess (n = 4), bile leakage (n = 2), and digestive fistula (leakage of ileorectostomy and small bowel perforation) (n = 2). However, no complications occurred at the site of the esophageal anastomosis (n = 15), gastric anastomosis (n = 15) or gastric suture (n = 7). No patient died postoperatively during the hospitalization period.
Conclusions: CRS in combination with HIPEC is associated with high postoperative morbidity; however, anastomosis following total or subtotal gastrectomy is safe in experienced centers. No leakages related to gastric resections occurred in this high-risk patient group.
Similar articles
-
[Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].Ann Ital Chir. 2008 Jul-Aug;79(4):231-9. Ann Ital Chir. 2008. PMID: 19093624 Italian.
-
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.Ann Surg Oncol. 2009 Feb;16(2):345-51. doi: 10.1245/s10434-008-0226-2. Epub 2008 Nov 19. Ann Surg Oncol. 2009. PMID: 19018599 Clinical Trial.
-
Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.J Surg Oncol. 2012 Aug 1;106(2):197-203. doi: 10.1002/jso.23062. Epub 2012 Feb 13. J Surg Oncol. 2012. PMID: 22331814
-
[Updated treatment of peritoneal carcinomas: a review].Minerva Chir. 2007 Dec;62(6):459-76. Minerva Chir. 2007. PMID: 18091656 Review. Italian.
-
Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.J Surg Oncol. 2009 Sep 15;100(4):317-20. doi: 10.1002/jso.21327. J Surg Oncol. 2009. PMID: 19697438 Review.
Cited by
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.World J Gastroenterol. 2016 Jan 21;22(3):1114-30. doi: 10.3748/wjg.v22.i3.1114. World J Gastroenterol. 2016. PMID: 26811651 Free PMC article. Review.
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination.Tumour Biol. 2013 Feb;34(1):463-9. doi: 10.1007/s13277-012-0571-4. Epub 2012 Oct 30. Tumour Biol. 2013. PMID: 23108893
-
Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations.Curr Oncol. 2024 Mar 9;31(3):1445-1459. doi: 10.3390/curroncol31030109. Curr Oncol. 2024. PMID: 38534942 Free PMC article. Review.
-
Comparison of the outcomes of cytoreductive surgery versus surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a propensity score matching analysis.Surg Endosc. 2021 Jun;35(6):2789-2796. doi: 10.1007/s00464-020-07712-3. Epub 2020 Jul 6. Surg Endosc. 2021. PMID: 32632486
-
Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies: a systematic review of randomized controlled trials.EXCLI J. 2021 Aug 19;20:1328-1345. doi: 10.17179/excli2021-4108. eCollection 2021. EXCLI J. 2021. PMID: 34650387 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical